Michael Leahy

Summary

Affiliation: Christie Hospital
Country: UK

Publications

  1. ncbi request reprint Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
    Michael Leahy
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, UK, and Erasmus University Medical Center, Rotterdam, Netherlands
    Eur J Cancer 43:308-15. 2007
  2. doi request reprint Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up
    P G Casali
    Department of Cancer Medicine, Istituto Nazionale dei Tumori, Milan, Italy
    Ann Oncol 19:ii35-8. 2008
  3. doi request reprint Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up
    P G Casali
    Department of Cancer Medicine, Istituto Nazionale dei Tumori, Milan, Italy
    Ann Oncol 19:ii89-93. 2008

Detail Information

Publications3

  1. ncbi request reprint Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
    Michael Leahy
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, UK, and Erasmus University Medical Center, Rotterdam, Netherlands
    Eur J Cancer 43:308-15. 2007
    ..In the non-GIST group, this PFS is in the range of other agents considered active in STS, and may predict for more substantial first line activity. Further investigation in STS other than GIST appears warranted...
  2. doi request reprint Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up
    P G Casali
    Department of Cancer Medicine, Istituto Nazionale dei Tumori, Milan, Italy
    Ann Oncol 19:ii35-8. 2008
  3. doi request reprint Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up
    P G Casali
    Department of Cancer Medicine, Istituto Nazionale dei Tumori, Milan, Italy
    Ann Oncol 19:ii89-93. 2008